Skip to main content
Premium Trial:

Request an Annual Quote

Epoch Terminates MGB Eclipse Probe Distribution Deal with Amersham

NEW YORK, Oct. 6 (GenomeWeb News) - Epoch Biosciences said today that it has terminated an arrangement under which its MGB Eclipse genetic analysis probe systems was distributed by Amersham Biosciences.

 

According to Epoch, the deal was ended because of Amersham's failure to meet contractually established sales goals for the system.  In August, the company disclosed that it anticipated revenues from Amersham would be insignificant for the rest of the year and that its projected revenues for the full-year 2003 would be between $8.5 million and $9.5 million.  Epoch said that this guidance remains unchanged.

 

Epoch CEO William Gerber said in a statement that the company is in discussions with other potential distribution partners for the MGB Eclipse product line.

 

 

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.